NasdaqGM:NAMSBiotechs
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing
NewAmsterdam Pharma Company N.V. reported past full-year 2025 results on February 18, showing sales of US$22.5 million and a net loss of US$203.82 million, while also filing an omnibus shelf registration for up to 5,719,966 common shares.
Despite lower revenue and continued losses, analysts highlighted management’s confidence in obicetrapib’s late-stage trials and regulatory path, underscoring its central role in the company’s future.
We’ll now examine how confidence in obicetrapib’s...